COMMUNIQUÉS West-GlobeNewswire

Forward Pharma Reports Full-Year 2017 Financial and Operational Results
30/04/2018
COPENHAGEN, Denmark, April 30, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq: FWP ) (“We” or “Forward” or the “Company”), today reported financial results for the year ended December 31, 2017. Net income for the [...]
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
30/04/2018
BURLINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets [...]
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
30/04/2018
SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) announced today that it will host a webcast and conference call to discuss the Company’s financial results [...]
Golden Leaf Reports Fiscal Year 2017 Results
30/04/2018
TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“GLH” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a leading cannabis oil solutions company built around recognized brands, today announced its [...]
AzurRx BioPharma Announces Proposed Public Offering of Common Stock
30/04/2018
BROOKLYN, N.Y., April 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ: AZRX ), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public [...]
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
30/04/2018
Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection Tafinlar + Mekinist [...]
National Brain Tumor Society Stresses Urgent Patient Needs and Experiences During Brain Tumor Awareness Month 2018
30/04/2018
Largest brain tumor nonprofit in the U.S. rallies supporters to raise their voices in support of the brain tumor community BOSTON, April 30, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest [...]
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
30/04/2018
Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48 Predictability data [...]
miRagen Therapeutics to Participate in Upcoming Investor Conferences
30/04/2018
BOULDER, Colo., April 30, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today [...]
AxoGen, Inc. Reports 2018 First Quarter Financial Results
30/04/2018
Record Q1 Revenue of $17.3 million, representing 41% growth over prior year ALACHUA, Fla., April 30, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical [...]
Eloxx Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
30/04/2018
WALTHAM, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX ) today announced the completion of its previously announced underwritten public offering of 5,899,500 shares of its [...]
Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
30/04/2018
DUBLIN, Ireland, April 30, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL ), “Avadel” or “the Company,” today announced that Greg Divis, Chief Operating Officer, and Mike Kanan, Chief Financial [...]
Theratechnologies’ CEO and CFO to Attend Bloom Burton Healthcare Investor Conference in Toronto
30/04/2018
MONTREAL, April 30, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) is pleased to announce that Luc Tanguay, President and Chief Executive Officer will make a presentation at the 2018 [...]
Le chef de la direction et le chef de la direction financière assisteront à la conférence d’investisseurs Bloom Burton à Toronto
30/04/2018
MONTRÉAL, 30 avr. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) est heureuse d’annoncer que Luc Tanguay, président et chef de la direction fera une présentation dans le cadre de la [...]
Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
30/04/2018
- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public Offering Raised [...]
New Mexico Cannabis Program on Pace to Break $100 Million
30/04/2018
Enrollment up 46 percent, patient sales up only 27 percent, restrictions on supply dampens sales ALBUQUERQUE, N.M., April 30, 2018 (GLOBE NEWSWIRE) -- The New Mexico Medical Cannabis Program patient revenues from the [...]
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
30/04/2018
Oral presentation of tolerability and immunogenicity data from a study of EDIT-101 following subretinal injection in non-human primates CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ [...]
AB Science reports today its annual financials as of 31 December 2017 and provides an update on its activities
30/04/2018
Paris, April 30, 2018 - 6.30pm 2017 revenues of 1,739 K€, an increase of 15.3% compared with 2016 Cash position of 38.8M€ as of 31 December 2017, plus 6.6M€ of 2017 tax credit to be reimbursed by the Public Finance [...]
AB Science annonce aujourd'hui ses résultats financiers annuels arrêtés au 31 décembre 2017 et présente l'actualité de ses activités
30/04/2018
Paris, le 30 avril 2018 - 18h30 Chiffre d'affaires de 1 739 K€ pour l'année 2017, en hausse de 15,3% par rapport à 2016 Trésorerie de 38,8M€ au 31 décembre 2017, à laquelle s'ajoutent 6,6M€ de crédit d'impôt 2017 en [...]

Pages